Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 67 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Care Regimen 12 Months Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant

NCT05260268
View directory record Official record
Conditions
Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
Interventions
TEST Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Terminated Phase 3 Interventional Results available

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT02013167
View directory record Official record
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Standard of Care Chemotherapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 5, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Perioperative Chemo and Pembrolizumab in Gastric Cancer

NCT02918162
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction
Interventions
Pembrolizumab, Standard of care chemotherapy regimen
Drug
Lead sponsor
Gulam Manji
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 5, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 5, 2026, 6:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

NCT01875237
View directory record Official record
Conditions
Leukemia, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 5, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 5, 2026, 6:17 AM EDT
Terminated Phase 1 Interventional Results available

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

NCT02188719
View directory record Official record
Conditions
Liver Transplantation
Interventions
Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 5, 2026, 6:17 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055
View directory record Official record
Conditions
Cancer
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2,206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 5, 2026, 6:17 AM EDT
Recruiting Phase 2 Interventional

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

NCT05541016
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Completed No phase listed Observational

Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer

NCT01471483
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
geriatric assessment and telephone call from nurse, geriatric assessment and no call from nurse
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
3
States / cities
Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 5, 2026, 6:17 AM EDT
Recruiting No phase listed Observational

Quantitative MRI for Myelofibrosis

NCT01973881
View directory record Official record
Conditions
Myelofibrosis
Interventions
T1 Weighted MRI (magnetic resonance imaging)
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 5, 2026, 6:17 AM EDT
Active, not recruiting Phase 2 Interventional

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT04462406
View directory record Official record
Conditions
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Interventions
Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab
Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
482
States / cities
Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Positive Steps to Enhance Problem Solving Skills

NCT03092531
View directory record Official record
Conditions
Adherence
Interventions
Positive STEPS
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
16 Years to 29 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 5, 2026, 6:17 AM EDT
Recruiting Phase 2 Interventional

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

NCT06902272
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
Diagnostic Test · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Interventions
LAI plus multi-drug regimen
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 5, 2026, 6:17 AM EDT
Completed Phase 1 Interventional

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

NCT03245892
View directory record Official record
Conditions
High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer
Interventions
Carboplatin and Paclitaxel, Nivolumab, Cytoreductive surgery, Ipilimumab
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 5, 2026, 6:17 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT07001748
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional Results available

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

NCT02410551
View directory record Official record
Conditions
Myeloproliferative Diseases
Interventions
Pacritinib, Busulfan, Questionnaires, Phone Calls, Allogeneic Stem Cell Transplantation, Fludarabine
Drug · Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 5, 2026, 6:17 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Interventions
AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

NCT06333678
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Sotorasib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

NCT04206813
View directory record Official record
Conditions
HPV Infection
Interventions
Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 5, 2026, 6:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

NCT02217410
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF), Corticosteroids (CS), anti-IL2 Induction
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Aurora, Colorado • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 5, 2026, 6:17 AM EDT